NVCT vs PNR · $304.5M cap vs P/E 18, rev $4.18B
Nuvectis Pharma Inc (NVCT) versus Pentair PLC (PNR) — a side-by-side from cached financials, not a winner call.
Nuvectis Pharma Inc (NVCT) is a biotechnology company listed on NASDAQ.
Pentair PLC (PNR) is a specialty industrial machinery company listed on NYSE.
NVCT does not have a complete income-statement cache yet.
Latest reported PNR revenue for 2025-12-31 was $4.18B. Net income was $653.8M. Revenue was up 2.3% from 2024-12-31 to 2025-12-31. PNR currently screens at market cap $11.86B and trailing P/E 18.4.
NVCT currently screens at market cap $304.5M. PNR currently screens at market cap $11.86B and trailing P/E 18.4.
Not investment advice. Open the NVCT and PNR stock pages for the full models.
Not investment advice.